Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.44 |
| ▸ | CCR2 | P41597 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31565984 | 0.94 | CCR2 (0.44) | NAMPTCCR2KCNH2FAPESR1 | |
| SCHEMBL31566094 | 0.92 | ESR1 (0.43) | CCR2KCNH2FAPESR1ESR2 | |
| SCHEMBL25969989 | 0.91 | NAMPT (0.42) | NAMPTCCR2KCNH2SCN9AESR1 | |
| SCHEMBL3992628 | 0.88 | NAMPT (0.48) | NAMPTKCNH2FAPESR1ESR2 | |
| SCHEMBL31565899 | 0.84 | LIPE (0.41) | NAMPTSCN9AFAPESR1ESR2 | |
| SCHEMBL31565989 | 0.83 | RORC (0.43) | NAMPTFAPESR1ESR2LIPE | |
| SCHEMBL31566005 | 0.82 | FAP (0.43) | NAMPTKCNH2SCN9AFAPESR1 | |
| SCHEMBL31566015 | 0.81 | CCR2 (0.46) | NAMPTCCR2KCNH2SCN9AESR1 | |
| SCHEMBL31565889 | 0.80 | ESR1 (0.47) | ESR1ESR2LIPE | |
| SCHEMBL31565857 | 0.79 | LIPE (0.45) | FAPESR1ESR2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | NAMPT 3316/4885CCR2 3845/4885KCNH2 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.